Jemperli’s was approved for the first-line indication last year, becoming the first immunotherapy for these patients, on the strength of data from Part 1 of the RUBY trial. The results showed ...

The European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...

AnaptysBio discovered Jemperli, which was licensed to TESARO ... dedicated to conducting cooperative clinical trials. GSK Oncology, R&D global head and senior vice-president Hesham Abdullah ...

European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...

Merck & Co's KEYNOTE-158 trial of Keytruda has underpinned another ... in on territory held by GlaxoSmithKline's rival drug Jemperli (dostarlimab), which was approved for patients with recurrent ...

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...

GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

We're proud Jemperli continues to redefine the treatment ... including histologies often excluded from clinical trials and had approximately 10% of patients with carcinosarcoma and 20% with ...

The approval broadens the previous indication for Jemperli plus chemotherapy in ... The company says RUBY Part 1 is the only clinical trial in this setting to show a clinically meaningful and ...